S

Sanofi

Global pharma company; vaccines and R&D

Rare Blood Disorders/Rare Hematology Thought Leader Liaison

Full-TimeUpdated on 10/23/2026Deadline 12/15/26
$146.3k - $211.3k
Senior
Bachelor's, Master's
Remote in USA
RemoteMust reside within the assigned territory or a reasonable distance as determined by leadership.
Growth & MarketingProduct Marketing

About the job

Requirements
  • Strong communication, organization, and project management skills.
  • Proven ability to work in a dynamic, fast-paced environment.
  • Ability to lead without formal authority and work collaboratively.
  • Ability to engage with top Key Opinion Leaders (KOLs) and other healthcare professionals (HCPs).
  • Expertise in creating and executing customer account plans.
  • Analytical and problem-solving skills, including identifying and acting on creative solutions.
  • Ability to establish credibility, connect information, and align multiple stakeholders to support adoption of new products, methods, and technologies.
  • Flexibility and ability to plan and adapt to changing market conditions.
  • Patient focus, urgency, commitment to high performance and results, and compliance.
  • High integrity and strong work ethic.
  • Bachelor's degree.
  • At least 5 years of work experience in field sales, product marketing, or medical/clinical work in the pharmaceutical or biotechnology space.
  • Prior experience interacting with KOLs.
  • Ability to travel to meetings, trainings, and programs as necessary (60–80%).
  • Valid driver's license.
  • Must reside within the assigned territory or a reasonable distance as determined by leadership.
Responsibilities
  • Coordinate function-specific activities with cross-functional colleagues in alignment with business and customer needs.
  • Identify, profile, and maintain long-term partnerships with KOLs and emerging leaders in hematology and allergy/immunology.
  • Identify systemic mastocytosis (SM) champions within the region.
  • Conduct on-label conversations to gather insights on disease diagnosis and treatment, therapeutic options, and product positioning across SM and immune thrombocytopenia (ITP).
  • Execute on-label strategic healthcare professional programming, including disease-state and product programming, as determined by brand needs.
  • Serve as a single point of contact to resolve commercial KOL issues.
  • Use a customer-centric, needs-based approach with targeted KOLs.
  • Plan and execute KOL engagements and executive encounters at local, regional, and national conferences, field visits, and other venues as directed.
  • Represent allergy/immunology and hematology/oncology KOL perspectives within the organization and share insights with stakeholders and cross-functional partners to inform brand strategy.
  • Lead long-term market-development efforts in assigned regions across the SM and ITP landscapes, focusing on high-potential centers and customers.
  • Develop and execute regional KOL customer-engagement plans and foster connections among multidisciplinary specialists who treat and manage SM and ITP patients.
  • Maintain understanding of regional market dynamics, including KOLs, institutional accounts, and multidisciplinary teams, and partner with sales leadership and commercial field teams to align regional market-development strategies.
  • Develop and execute regional marketing initiatives, including insight discovery, advisory boards, and roundtables.
  • Support regional congress planning and execution, including KOL insight-gathering engagements at priority hematology/oncology and allergy/immunology conferences, with Medical, Sales Leadership, Commercial Operations, and Brand Marketing.
  • Meet with assigned centers or customers to solicit feedback and adjust strategies.
  • Maintain clinical competence across SM, ITP, and acquired thrombotic thrombocytopenic purpura (aTTP).
  • Capture, analyze, and share customer insights aligned with brand priorities across SM and ITP.
  • Obtain feedback from targeted KOLs on new and existing brand-related strategies and materials; materials and programs must be approved by legal, compliance, and regulatory functions.
  • Capture and analyze competitive intelligence to inform strategy and activities.
  • Facilitate cross-functional planning, recruitment, and execution of regional and national advisory boards with HQ Marketing.
  • Identify, align, and recruit appropriate HCP/KOL consultants to meet marketing needs and project key performance indicators.
  • Collaborate cross-functionally to inform account strategies and plans through treatment-pathway discovery and insight generation to advance care in centers of excellence.
  • Assist with speaker-bureau management, including identifying and training or coaching promotional speakers using approved slide decks and materials.
  • Assist with speaker contracting when requested, including annual budget plans, recommendations, and nominations.
  • Coordinate and execute speaker training to ensure assigned speakers are competent, compliant, and up to date on new information.
  • Attend HCP speaker programs to observe, coach, and remediate speakers as needed to ensure effective content execution.
  • Assist with new content creation and updates and renewals of existing content.
  • Serve as the primary contact for high-volume speaker logistics and scheduling and coordinate cross-functionally to ensure streamlined communication.
  • Lead planning, execution, and follow-through of TLL-owned programs.
Desired Qualifications
  • Experience in rare diseases and/or hematology.
  • Allergy/immunology and/or hematology-oncology background.
  • Experience in marketing or leading marketing projects.
  • Academic-center focus and KOL-development experience.
  • Experience working within or building multidisciplinary treatment teams.
  • Cross-functional commercial background, such as marketing or sales leadership.
  • Master's degree in a related field.
  • Launch experience, including demonstrated success across multiple drug launches in applicable specialty markets.
  • Previous experience working as a Thought Leader Liaison.
  • KOL and/or speaker-management experience.
  • Project-management and vendor-management experience.
  • Understanding of oral targeted therapies with a requisite diagnostic component and ability to navigate complex market-access environments.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...